This site is intended for health professionals only

AstraZeneca acquires drug rights


Rights to US biotech company Targacept’s TC-5214 experimental antidepressant have been bought by AstraZeneca in a deal worth up to $1.24 billion (£720 million).

The drug, a nicotinic channel blocker that works in a novel way to tackle major depression, is due to enter final phase III clinical trials midway through next year.

Targacept will receive $200 million upfront if the deal wins US antitrust clearance, and further payments of $540 million and $500 million if certain sales milestones are achieved.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

Anglo-Swedish drugmaker AstraZeneca faces imminent loss of patent protection for heartburn treatment Nexium and Seroquel for schizophrenia, and badly needs a pipeline of profitable new drugs.

The antidepressant market is currently dominated by serotonin re-uptake inhibitors, such as Eli Lilly’s Prozac, which is now out of patent, but these drugs work well in less than half the population.

Copyright Press Association 2009

TC-5214 trial

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine